Mao Inhibitors + Tisotumab Vedotin Interaction
Moderateinteraction on record
Description
Concomitant use may increase unconjugated MMAE exposure, increasing risk of TIVDAK adverse reactions. Close monitoring for adverse reactions recommended.
Mechanism
MMAE is a CYP3A4 substrate; strong CYP3A4 inhibitors increase MMAE exposure
Source: NLP:tisotumab vedotin